Phenotypic Plasticity: Driver of Cancer Initiation, Progression, and Therapy Resistance.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 30554963.
- Also identified by DOI 10.1016/j.stem.2018.11.011 and PMC identifier 7297507.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Our traditional understanding of phenotypic plasticity in adult somatic cells comprises dedifferentiation and transdifferentiation in the context of tissue regeneration or wound healing. Although dedifferentiation is central to tissue repair and stemness, this process inherently carries the risk of cancer initiation. Consequently, recent research suggests phenotypic plasticity as a new paradigm for understanding cancer initiation, progression, and resistance to therapy. Here, we discuss how cells acquire plasticity and the role of plasticity in initiating cancer, cancer progression, and metastasis and in developing therapy resistance. We also highlight the epithelial-to-mesenchymal transition (EMT) and known molecular mechanisms underlying plasticity and we consider potential therapeutic avenues.
Medical subject headings
- Adaptation, Physiological
- Drug Resistance, Neoplasm
- Epithelial-Mesenchymal Transition
- Neoplasms
- Neoplastic Stem Cells